Cilastatin (Sepencil)
Cilastatin
Pharma Dynamics (Pty) Ltd
Registration
- Applicant
- Pharma Dynamics (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Sepencil 500 MG EACH VIAL CONTAINS: IMIPENEM MONOHYDRATE EQUIVALENT TO IMIPENEM 500,0 mg ,CILASTATIN SODIUM EQUIVALENT TO CILASTATIN 500,0 mgNone | 500 mg | 44081444/20.1.1/0814 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Cilastatin
Consolidated Schedules 06 July 2026, line 5807
S4: Imipenem
Consolidated Schedules 06 July 2026, line 6738
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(Z)-7-[(2R)-2-Amino-2-carboxyethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
Drag to rotate. Structure from PubChem CID 6435415.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.